Calcitonin gene-related peptide antagonism for acute treatment of migraine: a meta-analysis

International Journal of Neuroscience

Volumn 127, Issue 1, 2017, Pages 20-27

  Hong, Peiwei ^a   Liu, Yao ^b  

^a SICHUAN UNIVERSITY   (China)

^b Xindu Hospital of Traditional Chinese Medicine   (China)

Author keywords

5 HT; acute treatment; antagonism; calcitonin gene related peptide; CGRP; headache; migraine; triptans

Indexed keywords

BI 44370 TA; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; MK 3207; OLCEGEPANT; RIMEGEPANT; TELCAGEPANT; UNCLASSIFIED DRUG; CALCITONIN GENE RELATED PEPTIDE;

DRUG EFFICACY; HUMAN; META ANALYSIS; MIGRAINE; NAUSEA; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PHONOPHOBIA; PHOTOPHOBIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; ANTAGONISTS AND INHIBITORS; MIGRAINE DISORDERS; STATISTICS AND NUMERICAL DATA;

CALCITONIN GENE-RELATED PEPTIDE; HUMANS; MIGRAINE DISORDERS; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 84958049386     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2015.1137915     Document Type: Review

References (37)

1. Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010:a systematic analysis for the Global Burden of Disease Study 2010[J]. Lancet 2012;380(9859):2197–223.
2. Dodick DW, Goadsby PJ, Spierings EL, et al. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine:a phase 2, randomised, double-blind, placebo-controlled study[J]. Lancet Neurol 2014;13(9):885–92.
3. Ferrari MD, Goadsby PJ, Roon KI, et al. Triptans (serotonin, 5-HT1B/1D agonists) in migraine:detailed results and methods of a meta-analysis of 53 trials[J]. Cephalalgia 2002;22(8):633–58.
4. Kaiser EA, Russo AF., CGRP and migraine:could PACAP play a role too?[J]. Neuropeptides 2013;47(6):451–61.
5. Russell FA, King R, Smillie SJ, et al. Calcitonin gene-related peptide:physiology and pathophysiology[J]. Physiol Rev 2014;94(4):1099–142.
6. Aggarwal M, Puri V, Puri S., Serotonin and CGRP in migraine[J]. Ann Neurosci 2012;19(2):88–94.
7. Geppetti P, Rossi E, Chiarugi A, et al. Antidromic vasodilatation and the migraine mechanism[J]. J Headache Pain 2012;13(2):103–11.
8. Giamberardino MA, Martelletti P. Emerging drugs for migraine treatment. Expert Opin Emerg Drugs 2015;20(1):137–47.
9. Martelletti P., The therapeutic armamentarium in migraine is quite elderly. Expert Opin Drug Metab Toxicol 2015;11(2):175–7.
10. Lionetto L, Negro A, Palmisani S, et al. Emerging treatment for chronic migraine and refractory chronic migraine. Expert Opin Emerg Drugs 2012;17(3):393–406.
11. Antonaci F, Dumitrache C, De Cillis I, et al. A review of current European treatment guidelines for migraine[J]. J Headache Pain 2010;11(1):13–9.
12. Grande G, Labruijere S, Haanes KA, et al. Comparison of the vasodilator responses of isolated human and rat middle meningeal arteries to migraine related compounds. J Headache Pain 2014;15(1):22. doi:10.1186/1129-2377-15-22.
13. Cady R, Turner I, Dexter K, et al. An exploratory study of salivary calcitonin gene-related peptide levels relative to acute interventions and preventative treatment with onabotulinumtoxinA in chronic migraine[J]. Headache 2014;54(2):269–77.
14. Kageneck C, Nixdorf-Bergweiler BE, Messlinger K, et al. Release of CGRP from mouse brainstem slices indicates central inhibitory effect of triptans and kynurenate. J Headache Pain 2014;15(1):7. doi:10.1186/1129-2377-15-7.
15. Asghar MS, Hansen AE, Amin FM, et al. Evidence for a vascular factor in migraine[J]. Ann Neurol 2011;69(4):635–45.
16. Hansen JM, Hauge AW, Olesen J, et al. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura[J]. Cephalalgia 2010;30(10):1179–86.
17. Connor KM, Aurora SK, Loeys T, et al. Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial[J]. Headache 2011;51(1):73–84.
18. Connor KM, Shapiro RE, Diener HC, et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine[J]. Neurology 2009;73(12):970–7.
19. Dodick DW, Kost J, Assaid C, et al. Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments:application to patient-level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan[J]. Cephalalgia 2011;31(3):296–300.
20. Hewitt DJ, Aurora SK, Dodick DW, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine[J]. Cephalalgia 2011;31(6):712–22.
21. Ho AP, Dahlöf CG, Silberstein SD, et al. Randomized, controlled trial of telcagepant over four migraine attacks. Cephalalgia 2010;30(12):1443–57.
22. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine:a randomised, placebo-controlled, parallel-treatment trial[J]. Lancet 2008;372(9656):2115–23.
23. Ho TW, Ho AP, Chaitman BR, et al. Randomized, controlled study of telcagepant in patients with migraine and coronary artery disease[J]. Headache 2012;52(2):224–35.
24. Ho TW, Mannix LK, Fan X, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine[J]. Neurology 2008;70(16):1304–12.
25. Ho TW, Olesen J, Dodick DW, et al. Antimigraine efficacy of telcagepant based on patient's historical triptan response[J]. Headache 2011;51(1):64–72.
26. Marcus R, Goadsby PJ, Dodick D, et al. BMS-927711 for the acute treatment of migraine:a double-blind, randomized, placebo controlled, dose-ranging trial[J]. Cephalalgia 2014;34(2):114–25.
27. Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine[J]. N Engl J Med 2004;350(11):1104–10.
28. Troconiz IF, Wolters JM, Tillmann C, et al. Modelling the anti-migraine effects of BIBN 4096 BS:a new calcitonin gene-related peptide receptor antagonist[J]. Clin Pharmacokinet 2006;45(7):715–28.
29. Diener HC, Barbanti P, Dahlof C, et al. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks:results from a phase II study[J]. Cephalalgia 2011;31(5):573–84.
30. Negro A, Lionetto L, Simmaco M, et al. CGRP receptor antagonists:an expanding drug class for acute migraine? Expert Opin Investig Drugs 2012;21(6):807–18.
31. Moojen WA, Arts MP, Bartels RH, et al. Effectiveness of interspinous implant surgery in patients with intermittent neurogenic claudication:a systematic review and meta-analysis[J]. Eur Spine J 2011;20(10):1596–606.
32. Hong P, Liu Y, Li H., Comparison of the efficacy and safety between interspinous process distraction device and open decompression surgery in treating lumbar spinal stenosis:a meta analysis[J]. J Invest Surg 2015;28(1):40–9.
33. Edvinsson L, Warfvinge K., CGRP receptor antagonism and migraine therapy[J]. Curr Protein Pept Sci 2013;14(5):386–92.
34. Bell IM., Calcitonin gene-related peptide receptor antagonists:new therapeutic agents for migraine[J]. J Med Chem 2014;57(19):7838–58.
35. Tfelt-Hansen P., Excellent tolerability but relatively low initial clinical efficacy of telcagepant in migraine[J]. Headache 2011;51(1):118–23.
36. Dodick D, Lipton RB, Martin V, et al. Consensus statement:cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine[J]. Headache 2004;44(5):414–25.
37. Ho TW, Connor KM, Zhang Y, et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention[J]. Neurology 2014;83(11):958–66.